Alyeska Investment Group’s Argos Therapeutics, Inc. ARGS Stock Holding History

Alyeska Investment Group’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-200,000	Closed	-$180K	–	598
2018 Q1	$180K	Buy	200,000 +190,000	+1,900%	+$356K	﹤0.01%	436
2017 Q4	$600K	Hold	10,000	–	–	﹤0.01%	401
2017 Q3	$36K	Hold	10,000	–	–	﹤0.01%	452
2017 Q2	$73K	Hold	10,000	–	–	﹤0.01%	444
2017 Q1	$90K	Hold	10,000	–	–	﹤0.01%	464
2016 Q4	$980K	Hold	10,000	–	–	0.01%	425
2016 Q3	$994K	Buy	+10,000	New	+$1.04M	0.01%	417

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Alyeska Investment Group's ARGS Position: Q4 2016 in Review

Alyeska Investment Group sold out of Argos Therapeutics, Inc. (ARGS) in Q4 2016, closing a stake of 5,571 shares — an estimated $521K sold.

Alyeska Investment Group first reported a position in ARGS in Q1 2014 and held it in 9 quarters. The position peaked at $1.4M in Q1 2015. 52 funds tracked by Wall St. Rank hold ARGS as of Q4 2016.

Alyeska Investment Group reported no remaining Argos Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Alyeska Investment Group sold 5,571 Argos Therapeutics, Inc. shares in Q4 2016, an estimated $521K.
Alyeska Investment Group first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 9 quarters.
Alyeska Investment Group's Argos Therapeutics, Inc. position peaked at $1.4M in Q1 2015.
52 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q4 2016.

Based on Alyeska Investment Group's 13F filing for Q4 2016, filed 14 Feb 2017.